Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.
Genetic testing now pinpoints which AML patients face dire versus favorable odds, enabling doctors to tailor intensity of treatment and post-MPN AML deserves separate prognostic consideration.
A 10-year Mayo Clinic cohort of 545 intensively-treated AML patients demonstrates that next-generation sequencing prognostic value is critically dependent on AML subtype, with KRAS mutation conferring HR 8.8 for inferior survival and NPM1mut/FLT3wt conferring HR 0.3 for superior survival in primary non-CBF AML. Post-MPN AML showed uniquely dismal outcomes (CR/CRi 27%, 5-year survival 0%), strongly supporting its separation as a distinct prognostic category in clinical practice.
What the study was
- Study design
- retrospective_cohort
- Population
- AML patients treated with intensive chemotherapy, Mayo Clinic 2015-2025
- Sample size
- 545
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Am J Hematol
Why it surfaced
Large real-world institutional cohort from a top academic center validates subtype-specific NGS utility and identifies KRAS mutation as an underappreciated adverse prognostic factor in intensive-chemotherapy AML; directly actionable for risk stratification and treatment individualization in this high-unmet-need disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.